Disease

Behcet's Syndrome

Late-stage therapeutic developmentEmerging research

MeSHBehcet Syndrome

Publications

Clinical trials

2023

Latest publication

Latest activity

beta

Recent clinical, regulatory, research and industry developments relating to this disease.

The roles of immune cells in Behçet's disease.

Research2023-10-09Advances in rheumatology (London, England)

What's happening now

An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.

Executive briefingUpdating summary…Momentum: Low

Key developments

1 clinical trial expected to report results, the earliest in Q4 2027.

Upcoming Milestones

Q4 2027Randomized Controlled Multicenter Study Comparing Steroid Therapy Plus Anticoagulants to Steroid Therapy Alone in Deep Venous Thrombosis of Behçet's Syndrome

Major developments

Upcoming trial readoutHigh impact

Randomized Controlled Multicenter Study Comparing Steroid Therapy Plus Anticoagulants to Steroid Therapy Alone in Deep Venous Thrombosis of Behçet's Syndrome

Results expected Q4 20272026-04-23

Major trial resultsHigh impact

To Evaluate the Efficacy, Safety, and Pharmacokinetics of TA-650 in Patients With Behcet's Disease ( BD ) With Special Lesions After the Administration of TA-650

Results posted2026-01-07

Clinical Milestones3View

Results posted 1

2026-01-07To Evaluate the Efficacy, Safety, and Pharmacokinetics of TA-650 in Patients With Behcet's Disease ( BD ) With Special Lesions After the Administration of TA-650Results posted

Results expected 1

2026-04-23Randomized Controlled Multicenter Study Comparing Steroid Therapy Plus Anticoagulants to Steroid Therapy Alone in Deep Venous Thrombosis of Behçet's SyndromeResults expected Q4 2027

Recently completed 1

2026-06-01Efficacy and Safety of Tocilizumab and Tofacitinib in the Treatment of Patients With Vascular Behçet's SyndromePrimary completion

Activity timeline3

2026-06-01ClinicalEfficacy and Safety of Tocilizumab and Tofacitinib in the Treatment of Patients With Vascular Behçet's SyndromePrimary completion
2026-04-23ClinicalRandomized Controlled Multicenter Study Comparing Steroid Therapy Plus Anticoagulants to Steroid Therapy Alone in Deep Venous Thrombosis of Behçet's SyndromeResults expected Q4 2027
2026-01-07ClinicalTo Evaluate the Efficacy, Safety, and Pharmacokinetics of TA-650 in Patients With Behcet's Disease ( BD ) With Special Lesions After the Administration of TA-650Results posted

Clinical trials

9 sponsors · 0 new · 0 completed in the last 12 months (net +0)

The current development programme across all trial phases.

Clinical programme

All trials

Active

Late-stage

Completed

Late-stage studies

Randomized Controlled Multicenter Study Comparing Steroid Therapy Plus Anticoagulants to Steroid Therapy Alone in Deep Venous Thrombosis of Behçet's Syndrome

Phase 3 · Recruiting · Assistance Publique - Hôpitaux de Paris

To Evaluate the Efficacy, Safety, and Pharmacokinetics of TA-650 in Patients With Behcet's Disease ( BD ) With Special Lesions After the Administration of TA-650

Phase 3 · Completed · Tanabe Pharma Corporation

Recruiting

Randomized Controlled Multicenter Study Comparing Steroid Therapy Plus Anticoagulants to Steroid Therapy Alone in Deep Venous Thrombosis of Behçet's Syndrome

Phase 3 · Recruiting · Assistance Publique - Hôpitaux de Paris

A Multi-center, Prospective, Open-label, Randomized Study to Explore Efficacy and Safety of Baricitinib in Refractory Intestinal Behçet's Syndrome Patients

Phase 2 · Recruiting · Peking Union Medical College Hospital

Efficacy and Safety of Tocilizumab and Tofacitinib in the Treatment of Patients With Vascular Behçet's Syndrome

Phase 2 · Recruiting · Peking Union Medical College Hospital

Recently completed

Upadacitinib for Refractory Behcet's Syndrome: a Prospective Pilot Open-label Study

Phase 2 · Completed · Liu Tian

Uses of Tacrolimus in Treatment of Oral Ulcers in Behcet Disease

N/A · Completed · Assiut University

To Evaluate the Efficacy, Safety, and Pharmacokinetics of TA-650 in Patients With Behcet's Disease ( BD ) With Special Lesions After the Administration of TA-650

Phase 3 · Completed · Tanabe Pharma Corporation

A Phase 2, Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel-group Study Followed by an Active-Treatment Extension to Evaluate the Efficacy and Safety of Apremilast(CC-10004) in the Treatment of Behçet Disease

Phase 2 · Completed · Amgen

Phase II Study, Evaluation of Low Dose Natural Human Interferon Alpha Administered by the Oral Mucosal Route in the Treatment of Behçet's Disease

Phase 2 · Completed · Nobel Pharmaceuticals

Research activity

1 papers

Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.

Most influential

The roles of immune cells in Behçet's disease.

Advances in rheumatology (London, England) · 2023 · 11 cites

Recent publications

The roles of immune cells in Behçet's disease.

Advances in rheumatology (London, England) · 2023 · 11 cites

Major themes1

Behcet Syndrome1

Leading journals1

Advances in rheumatology (London, England)1

Leading researchers2

Guan JL1
Hu D1

Affiliations (unnormalised)1

Huadong Hospital affiliated with Fudan University1

Reference

Authoritative identity, definition & identifiers.

Defined in MeSH

Rare chronic inflammatory disease involving the small blood vessels. It is of unknown etiology and characterized by mucocutaneous ulceration in the mouth and genital region and uveitis with hypopyon. The neuro-ocular form may cause blindness and death. SYNOVITIS; THROMBOPHLEBITIS; gastrointestinal ulcerations; RETINAL VASCULITIS; and OPTIC ATROPHY may occur as well.

Identifiers

MeSHBehcet Syndrome

References & data sources

Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
Related entities are derived from literature co-mention (studied together) — associative, not causal.